{"id":"NCT04626297","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)","officialTitle":"A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-11-17","primaryCompletion":"2022-08-03","completion":"2022-09-30","firstPosted":"2020-11-12","resultsPosted":"2023-08-28","lastUpdate":"2023-10-17"},"enrollment":254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Atopic Dermatitis"],"interventions":[{"type":"DRUG","name":"Lebrikizumab","otherNames":["LY3650150","DRM06"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lebrikizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The reason for this study is to assess the impact of lebrikizumab on vaccine immune response in adult participants with moderate to severe atopic dermatitis (AD).","primaryOutcome":{"measure":"Percentage of Participants Who Develop a Booster Response to Tetanus Toxoid 4 Weeks After Tdap (Tetanus-diphtheria-pertussis) Vaccine Administration","timeFrame":"Week 16","effectByArm":[{"arm":"Placebo","deltaMin":73.4,"sd":null},{"arm":"Lebrikizumab 250 mg","deltaMin":73.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":16},"locations":{"siteCount":85,"countries":["United States"]},"refs":{"pmids":["39009804"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/589axvNecFXMpOxA4PGIx3"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":127},"commonTop":["Dermatitis atopic","Covid-19","Nasopharyngitis","Headache","Fatigue"]}}